Literature DB >> 21881839

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Mahmoud M Iravani1, Peter Jenner.   

Abstract

A significant proportion of patients with Parkinson's disease (PD) receiving dopamine replacement therapy in the form of levodopa develop dyskinesia that becomes a major complicating factor in treatment. Dyskinesia can only be effectively treated by a reduction in drug dose, which limits efficacy, by co-administration of the weak NMDA antagonist amantadine or by surgical treatment (pallidotomy, DBS). This raises the important question of why dyskinesia occurs in PD and how it can be avoided or suppressed by pharmacological treatment. This review assesses some of the mechanisms that underlie dyskinesia induction and expression from presynaptic changes in dopaminergic neurones to postsynaptic alterations in basal ganglia function and examines potential approaches to prevention and treatment. These include glutamatergic approaches where agents that directly or indirectly alter glutamatergic neurotransmission modify the intracellular influx of Ca(2+) and reduce the formation of nitric oxide by neuronal nitric oxide synthase that may form an integral component of the complex cascade of events leading to dyskinesia. There is increasing evidence for the role of serotoninergic neurones in dyskinesia induction related to non-physiological formation and release of dopamine and serotoninergic agonists can modify dyskinesia expression. Similarly, noradrenergic receptors may serve to alter dyskinesia intensity and α-2-adrenoceptor antagonists alter the expression of levodopa-induced dyskinesia in both experimental models of PD and in man. Finally, other potential approaches to dyskinesia treatment based on manipulation of opiate, cannabinoid, adenosine and histamine receptors are considered. The conclusion is that the cause of levodopa-induced dyskinesia remains to be fully elucidated and that new approaches to treatment through non-dopaminergic mechanisms are required to control the onset and expression of involuntary movements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21881839     DOI: 10.1007/s00702-011-0698-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  431 in total

1.  Alpha2-adrenoceptor activation increases a cationic conductance and spontaneous GABAergic synaptic activity in dopaminergic neurones of the rat substantia nigra.

Authors:  L Cathala; A Guyon; D Eugene; D Paupardin-Tritsch
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

2.  Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Authors:  C Warren Olanow; Philippe Damier; Christopher G Goetz; Thomas Mueller; John Nutt; Olivier Rascol; Alexandru Serbanescu; Frieda Deckers; Hermann Russ
Journal:  Clin Neuropharmacol       Date:  2004 Mar-Apr       Impact factor: 1.592

3.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.

Authors:  L Verhagen Metman; P Del Dotto; P van den Munckhof; J Fang; M M Mouradian; T N Chase
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

4.  Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

Authors:  R Grondin; P J Bédard; A Hadj Tahar; L Grégoire; A Mori; H Kase
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

5.  Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation.

Authors:  L Trabace; K M Kendrick
Journal:  J Neurochem       Date:  2000-10       Impact factor: 5.372

6.  Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain.

Authors:  F C Zhou; S Bledsoe; J Murphy
Journal:  Brain Res       Date:  1991-08-09       Impact factor: 3.252

7.  Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.

Authors:  M A Silverdale; A R Crossman; J M Brotchie
Journal:  Exp Neurol       Date:  2002-03       Impact factor: 5.330

8.  Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.

Authors:  Sylvia Navailles; Bernard Bioulac; Christian Gross; Philippe De Deurwaerdère
Journal:  Neurobiol Dis       Date:  2010-01-22       Impact factor: 5.996

9.  The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.

Authors:  Kerstin Buck; Patrizia Voehringer; Boris Ferger
Journal:  J Neurochem       Date:  2009-11-06       Impact factor: 5.372

10.  G-protein-coupled receptors: past, present and future.

Authors:  Stephen J Hill
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

View more
  38 in total

1.  Mechanisms underlying and medical management of L-Dopa-associated motor complications.

Authors:  Manfred Gerlach; Peter Riederer; Dieter Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-12       Impact factor: 3.575

2.  The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.

Authors:  Manfred Gerlach; Paul Halley; Peter Riederer; Maarten van den Buuse
Journal:  J Neural Transm (Vienna)       Date:  2012-05-17       Impact factor: 3.575

3.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

4.  Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.

Authors:  Maryka Quik; Carla Campos; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

5.  The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii.

Authors:  Y Hiroshima; H Miyamoto; F Nakamura; D Masukawa; T Yamamoto; H Muraoka; M Kamiya; N Yamashita; T Suzuki; S Matsuzaki; I Endo; Y Goshima
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 6.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

7.  Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Authors:  Elaine Del-Bel; Fernando Eduardo Padovan-Neto; Raphael Escorsim Szawka; Célia Aparecida da-Silva; Rita Raisman-Vozari; Janete Anselmo-Franci; Angélica Caroline Romano-Dutra; Francisco Silveira Guimaraes
Journal:  Neurotox Res       Date:  2013-06-27       Impact factor: 3.911

8.  Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.

Authors:  Mariza Bortolanza; Keila D Bariotto-Dos-Santos; Maurício Dos-Santos-Pereira; Célia Aparecida da-Silva; Elaine Del-Bel
Journal:  Neurotox Res       Date:  2016-04-06       Impact factor: 3.911

9.  The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Authors:  Sara Sanz-Blasco; Melina P Bordone; Ana Damianich; Gimena Gomez; M Alejandra Bernardi; Luciana Isaja; Irene R Taravini; Diane P Hanger; M Elena Avale; Oscar S Gershanik; Juan E Ferrario
Journal:  Mol Neurobiol       Date:  2017-08-24       Impact factor: 5.590

10.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.